文献速递头痛与眩晕

静脉氢吗啡酮与丙氯拉嗪联合苯海拉明治疗急诊偏头痛的随机研究

Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine.
PubMed 文献 · Neurology · 2017-10-18

该随机双盲试验在纽约市两家急诊科进行,纳入符合国际偏头痛诊断标准且近一月未使用阿片类药物的患者,比较静脉氢吗啡酮1mg与丙氯拉嗪10mg联合苯海拉明25mg的疗效。主要结局为持续头痛缓解(2小时内头痛达轻度或无且48小时无需急救药物维持)。数据监测委员会在入组127例后终止试验,丙氯拉嗪组持续缓解率60%(37/62),氢吗啡酮组31%(20/64),差异28%(95%CI 12-45),需治疗人数4(95%CI 2-9)。结论认为静脉氢吗啡酮疗效显著低于丙氯拉嗪联合苯海拉明,不应作为急诊偏头痛的一线治疗。

要点

  • 丙氯拉嗪联合苯海拉明持续头痛缓解率60%,氢吗啡酮仅31%。
  • 差异28%(95%CI 12-45),需治疗人数4(95%CI 2-9)。
  • 氢吗啡酮不应作为急诊偏头痛的一线治疗。

核心结论

  • 静脉氢吗啡酮治疗急诊急性偏头痛的疗效显著低于丙氯拉嗪联合苯海拉明,不应作为一线治疗。

研究设计与样本

  • 随机双盲试验,在纽约市2家急诊科进行,计划中期分析后因疗效差异提前终止,最终纳入127例患者。
  • 患者符合国际偏头痛诊断标准且近1个月未使用阿片类药物,随机接受氢吗啡酮1mg或丙氯拉嗪10mg联合苯海拉明25mg。

主要发现

  • 主要结局持续头痛缓解在丙氯拉嗪组为37/62(60%),氢吗啡酮组为20/64(31%)。
  • 两组率差28%(95%CI 12-45),需治疗人数为4(95%CI 2-9)。

关键数值与推荐

  • 持续头痛缓解定义为给药后2小时内头痛程度达轻度或无,且48小时内维持该水平且无需急救药物。
  • 苯海拉明25mg用于预防丙氯拉嗪常见的静坐不能副作用。

临床怎么用

  • 急诊成人偏头痛且近1个月未使用阿片类药物者,优先选择静脉丙氯拉嗪联合苯海拉明而非氢吗啡酮。

局限性

  • 试验因中期分析显示疗效差异而提前终止,最终样本量127例。
  • 研究仅纳入近1个月未使用阿片类药物的患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine. METHODS: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients. RESULTS: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60%) participants and in the hydromorphone arm by 20 of 64 (31%) participants (difference 28%, 95% confidence interval 12-45, number needed to treat 4, 95% confidence interval 2-9). CONCLUSIONS: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy. CLINICALTRIALSGOV IDENTIFIER: NCT02389829. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Friedman BW, Irizarry E, Solorzano C, et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017. PMID: 29046364. doi:10.1212/WNL.0000000000004642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。